Pfizer: EU approves acquisition of Seagen
(CercleFinance.com) - The European Commission has unconditionally approved Pfizer's proposed acquisition of Seagen under EU Merger Regulations, concluding that the transaction would not raise competition concerns in the European Economic Area.
Seagen specializes in oncology therapies, mainly antibody-drug conjugates ("ADCs"). Pfizer's oncology portfolio largely consists of hormone therapies, immunotherapies and targeted therapies.
In the EEA, the companies' marketed and pipeline products overlap in the treatment of several types of cancer (including breast, bladder, colorectal, cervical and lung cancer), as well as lymphoma and leukemia. By acquiring Seagen's ADC technology, Pfizer aims to diversify its portfolio and accelerate the development and commercialization of Seagen's ADC drugs.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Seagen specializes in oncology therapies, mainly antibody-drug conjugates ("ADCs"). Pfizer's oncology portfolio largely consists of hormone therapies, immunotherapies and targeted therapies.
In the EEA, the companies' marketed and pipeline products overlap in the treatment of several types of cancer (including breast, bladder, colorectal, cervical and lung cancer), as well as lymphoma and leukemia. By acquiring Seagen's ADC technology, Pfizer aims to diversify its portfolio and accelerate the development and commercialization of Seagen's ADC drugs.
Copyright (c) 2023 CercleFinance.com. All rights reserved.